Price J, Linder G, Li W, et al
From there, the shift toward actual control quickly comes into focus, as inflammation declines, weight comes off and movement becomes easier
They suggested that GLP-1 could cause a decrease in blood pressure
Moreover, HGF gene transfer with viral vectors reduces pain and inflammation in a neuropathic model (Tsuchihara et al., 2008), promotes neurite extension, and increases synaptogenesis in a stroke model (Shimamura et al., 2006)
Simultaneously, strategic CDMO moves are underway: Novo Holdings $16.5 billion acquisition of Catalent (plus an $11 billion transfer of three Catalent plants) was explicitly aimed at ramping Wegovy/Ozempic output ( [10] ) ( [11] )